Previous close | 0.6900 |
Open | 0.8100 |
Bid | 0.6200 |
Ask | 0.6900 |
Strike | 37.00 |
Expiry date | 2025-06-20 |
Day's range | 0.6900 - 0.8100 |
Contract range | N/A |
Volume | |
Open interest | 674 |
Novavax stock is soaring on news the FDA set a deadline by which to approve or reject its COVID-19 vaccine.
A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's two-drug oral treatment would ease symptoms of long COVID after anecdotal reports of patients who said Paxlovid helped them.
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.